Mar Fabregas – General Manager, STADA Spain
STADA’s general manager for Spain, Mar Fabregas, reveals how the acquisition of parts of GSK and Sanofi’s portfolio is helping the global generics company better compete in consumer health. In…
Address Barcelona: Frederic Mompou, 5, 08960 Sant Just Desvern (Barcelona), España
Tel: 934 738 889
Address Madrid: Paseo de la Castellana 135, 28046 Madrid, España
Tel: 915 720 893
Website: https://www.stada.es/
Email: info@stada.es
STADA is an international company with more than 117 years experience and is dedicated to the development of generic drugs. Worldwide, STADA is represented in more than 30 countries in about 50 subsidiaries. Branded products such as Algesal®, Grippostad® Hirudoid®, and Neositrin®are among the top sellers in their respective product categories. Since 2010 STADA has amplified its portfolio through the research and development of skin care products.
STADA’s general manager for Spain, Mar Fabregas, reveals how the acquisition of parts of GSK and Sanofi’s portfolio is helping the global generics company better compete in consumer health. In…
The latest stories from Spain’s booming healthcare and life science industry. Spain still leads Europe for clinical trial numbers, while a recent meeting between Spanish PM Pedro Sánchez and Roche…
As China and the US attract an increasing share of commercial clinical trials, Europe is fighting to reclaim its spot as a global research leader. While Europe has world-class hospitals…
Dr Arcadi Navarro is a leading figure in modern Alzheimer’s research, heading efforts at the Pasqual Maragall Foundation in Barcelona and its university partners. His work spans genomics, bioinformatics, neurotropic…
A roundup of the biggest pharma news from Spain, including Grifols’ comeback after a turbulent 2024 when the company lost 30 percent of its market value; Almirall’s revenue and value…
While Europe has lost some of its global share of clinical trials to China and the US, it remains a clinical research stronghold. Three years into the Accelerating Clinical Trials…
A roundup of some of the top stories coming out of Spain’s life sciences sector, including Brookfield’s ongoing interest in Grifols; Rovi’s change of heart about selling its CDMO business;…
Almost 2,500 attendees flocked to Madrid last week for the 2024 edition of Clinical Trials on Alzheimer’s Disease (CTAD). The first European edition of the conference since 2018 was punctuated…
Some of the biggest stories coming out of Spain’s pharma industry, including Brookfield’s bid for a troubled Grifols; Esteve’s Spanish plant expansion; Rovi’s offers for a potential buyout of its…
A roundup of the biggest stories emerging from Spain’s pharma industry: Grifols pushes to improve governance after accusations of overstated earnings; Rovi and Insud join forces to create Spain’s first…
Brazilian national Maria Fernanda Prado, who began her career in pharma more than 20 years ago, has been at Janssen/Johnson & Johnson for more than half of that time. She…
Thanks to what AstraZeneca country president Rick Suarez called a “thriving life-science eco-system and highly-skilled talent pool,” along with Spain’s leading position in clinical trials, the British Big Pharma is…
Having forged a solid position in clinical research in 2020 and 2021 when it became the fourth nation in the world and the first in Europe for studies conducted around…
See our Cookie Privacy Policy Here
